GLP-1 Market
LLY $1409.38 ▼ -0.1% NVO $40.19 ▼ -0.6% PFE $30.00 ▼ -2.2% VKTX $26.09 ▼ -2.8% KLRA $12.58 ▲ +3.5% GPCR $20.35 ▼ -0.6% RHHBY $59.18 ▼ -2.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SHR-3167

SHR-3167

Company
Jiangsu HengRui Medicine Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 4, 2026

Find a Clinical Trial Near Me

See recruiting studies for SHR-3167 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07032688

    A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 55 participants Est. completion 2027-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07489482

    A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 60 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT05996380

    A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 52 participants Est. completion 2024-04-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06688123

    Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 275 participants Est. completion 2026-04-22 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07018453

    A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 173 participants Est. completion 2026-05 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07472725

    A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 102 participants Est. completion 2027-02 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07588906

    To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2024-07-23 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Not yet recruiting NCT NCT07913061

    A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 680 participants Est. completion 2028-02 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.